Fig. 7
HOXA10 enhanced Smad2/3 expression in the cell nucleus and promoted the deposition of METTL3. a Western blot suggested that HOXA10 activated the Smad pathway but could be suppressed by TGFB2 inhibitor. b Confocal immunofluorescent staining indicated that HOXA10 promoted Smad2/3 translocation into the cell nucleus. c The colorimetric m6A assay demonstrated that HOXA10 elevated the m6A levels in GC cells. d Western blot showed that HOXA10 elevated METTL3 expression but could be repressed by TGFB2 inhibitor. e CoIP experiment revealed that Smad2/3 interacted with METTL3 in the nucleus of BGC823 cells. f ChIP-qPCR assay revealed the potential binding sites of Smad2/3 in the METTL3 promoter region. g Western blot showed that the protein expressions of P-Smad2/3 and METTL3 in AGS-HOXA10 cells were both reduced after being treated with ITD-1. Scale bars: 25 μm. ***P < 0.001